¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"new mutation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • genetic mutation
    À¯Àüµ¹¿¬º¯ÀÌ
  • genomic mutation
    À¯Àüüµ¹¿¬º¯ÀÌ
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • loss-of-function mutation
    ±â´É¼Ò½Çµ¹¿¬º¯ÀÌ
  • missense mutation
    °ú¿Àµ¹¿¬º¯ÀÌ, ¹Ì½º¼¾½ºµ¹¿¬º¯ÀÌ
  • mutation
    µ¹¿¬º¯ÀÌ
  • mutation genetics
    º¯ÀÌÀ¯ÀüÇÐ
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • natural mutation
    ÀÚ¿¬µ¹¿¬º¯ÀÌ
  • nonsense mutation
    ¹«Àǹ̵¹¿¬º¯ÀÌ, ³Í¼¾½ºµ¹¿¬º¯ÀÌ
  • plaque morphology mutation
    ÆÇÇüŵ¹¿¬º¯ÀÌ, ÇöóÅ©Çüŵ¹¿¬º¯ÀÌ
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • polar mutation
    ±Ø¼ºµ¹¿¬º¯ÀÌ
  • population mutation
    Áý´Üµ¹¿¬º¯ÀÌ
  • recessive mutation
    ¿­¼ºµ¹¿¬º¯ÀÌ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mutation genetics
    º¯ÀÌÀ¯ÀüÇÐ
  • host range mutation
    ¼÷ÁÖ¹üÀ§º¯ÀÌ, ¼÷ÁÖ¿ªº¯ÀÌ
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • loss mutation
    »ó½Çµ¹¿¬º¯ÀÌ
  • mutation
    µ¹¿¬º¯ÀÌ
  • missense mutation
    °ú¿Àµ¹¿¬º¯ÀÌ
  • multiple allelic mutation
    ¹µ¸Â¼¶µ¹¿¬º¯ÀÌ
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • natural mutation
    ÀÚ¿¬µ¹¿¬º¯ÀÌ
  • nonsense mutation
    ¹«Àǹ̵¹¿¬º¯ÀÌ
  • plaque morphology mutation
    (¢¡plaque-type mutation) ÇöóÅ©Çüµ¹¿¬º¯ÀÌ
  • plaque-type mutation
    ÇöóÅ©Çüµ¹¿¬º¯ÀÌ
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • polar mutation
    ±Ø¼ºµ¹¿¬º¯ÀÌ
  • population mutation
    Áý´Ü±ºµ¹¿¬º¯ÀÌ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • drift mutation
    ¿¬¼Óº¯ÀÌ(ææáÙܨì¶).
  • frameshift mutation
    ÇØµ¶Æ² µ¹¿¬º¯ÀÌ, ÇÁ·¹ÀÓ½¬ÇÁÆ® µ¹¿¬º¯ÀÌ
  • frequency, mutation
    µ¹¿¬º¯À̺óµµ
  • gene mutation
    ÇØºÎ
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ(ÔÍæÔܨì¶).
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ.
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ.
  • gene mutation
    À¯ÀüÀÚ(µ¹¿¬)º¯ÀÌ
  • genetic mutation
    À¯ÀüÀû µ¹¿¬º¯ÀÌ
  • genomic mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ
  • host range mutation
    ¼÷ÁÖ¿ªº¯ÀÌ
  • induced mutation
    À¯¹ß¼º µ¹¿¬º¯ÀÌ.
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • lethal mutation
    Ä¡»çµ¹¿¬º¯ÀÌ(¡­ÔÍæ×ܨì¶).
  • lethal mutation
    Ä¡»ç µ¹¿¬º¯ÀÌ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lethal mutation
    Ä¡»çº¯ÀÌ(öÈÞÝܨì¶)
  • lethal mutation model
    Ä¡»çº¯ÀÌ(öÈÞÝܨì¶)¸ðµ¨
  • missense mutation
    ¿ÀÀκ¯ÀÌ(è¦ìãܨì¶)
  • mutation
    º¯ÀÌ(ܨì¶)
  • mutation distance
    º¯ÀÌ(ܨì¶)°Å¸®
  • mutation frequency
    º¯À̺óµµ(ܨì¶ÞºÓø)
  • mutation index
    º¯ÀÌÁö¼ö(ܨì¶ò¦â¦)
  • mutation rate
    º¯ÀÌÀ²(ܨì¶ëÒ)
  • mutation stabilization
    º¯À̾ÈÁ¤È­(ܨì¶äÌïÒûù)
  • mutation theory
    º¯ÀÌ·Ð(ܨì¶Öå)
  • neutral mutation
    Á߸³º¯ÀÌ(ñ騡܍ì¶)
  • nonsense mutation
    ³Í¼¾½º º¯ÀÌ(ܨì¶)
  • ochre mutation
    ¿À¿ìÄ¿º¯ÀÌ(ܨì¶)
  • phase shift mutation
    »óÀ̵¿ º¯ÀÌ(ßÓì¹ÔÑܨì¶)
  • pleiotropic mutation
    ´ÙÇüÁú¼º º¯ÀÌ(Òýû¡òõàõܨì¶)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TRNB Transient Respiratory distress of New Born
TTNB Transient Tachypnea of New Born
ANDA Abbreviated New Drug Application
IND indomethacin; industrial medicine; investigational new drug
NAD neutrophil actin dysfunction; new antigenic determinant; nicotinamide adenine dinucleotide; nicotini...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MCR mutation cluster region
M(f) mutation frequency
Tfm testicular feminization mutation
NJ A/New Jersey
IND Investigational New Drug
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mutation rate
    º¯ÀÌÀ², µ¹¿¬º¯ÀÌÀ²
  • ochre mutation
    ¿À¿ìÄ¿ µ¹¿¬º¯ÀÌ
  • reading framework mutation
    ÆÇµ¶ °ñ°Ý ±¸Á¶ À̵¿ µ¹¿¬º¯ÀÌ
  • reverse mutation
    ȯ¿ø µ¹¿¬ º¯ÀÌ
  • silent mutation
    ¹«ÁõÈÄ µ¹¿¬º¯ÀÌ
  • somatic mutation
    ü ¼¼Æ÷ µ¹¿¬º¯ÀÌ
  • suppressor mutation
    ¾ïÁ¦ µ¹¿¬º¯ÀÌ
  • temperature-sensitive mutation
    ¿Âµµ ¹Î°¨ µ¹¿¬º¯ÀÌ
  • visible mutation
    °¡½Ã¼º µ¹¿¬º¯ÀÌ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
New York Heart Association classification A functional classification to assess cardiovascular disability. Class I: patients with cardiac disease without limitation of physical activity. Ordinary activity does not cause symptoms. Class II: patients with cardiac disease with slight limitation of activity; comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or angina. Class III: patients with cardiac disease producing marked limitation of activity: comfortable at rest. Less than ordinary physical activity causes symptoms. Class IV: patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms may be present even at rest.
(05 Mar 2000)
new zealand A group of islands in the South Pacific Ocean. New Zealand flax.
<botany> A myrtaceous shrub (Leptospermum scoparium) of new Zealand and Australia, the leaves of which are used as a substitute for tea.
Source: Websters Dictionary
(01 Mar 1998)
New Zealand mice Inbred strains of mice, either black (NZB) or white (NZW), unique among strains used in experimental immunology because of their proclivity to spontaneous immunologic abnormalities and disorders including systemic lupus erythematosus similar to that found in humans.
(05 Mar 2000)
investigational new drug Status given an experimental drug after the FDA approves an application for testing it in people.
(09 Oct 1997)
investigational new drug application An application that must be submitted to a regulatory agency (the FDA in the united states) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured.
(12 Dec 1998)
acquired mutation A change in a gene or chromosome that occurs in a single cell after the conception of the individual. That change is then passed along to all cells descended from that cell. Acquired mutations are involved in the development of cancer.
(12 Dec 1998)
addition-deletion mutation <molecular biology> A type of mutation that results from insertion or deletion of a single nucleotide into, or from, an open reading frame in the normal DNA sequence.
Normally, the genetic code is read in the wrong frame, three nucleotides at a time, and the entire sequence downstream of the mutation, is translated into a polypeptide with a garbled amino acid sequence from the mutated codon onwards. These mutations may be induced by certain types of mutagens or may occur spontaneously and usually result in the generation, downstream, of nonsense, chain termination codons.
Synonym: addition mutation, addition-deletion mutation, deletion mutation, reading-frameshift mutation.
(21 Jun 2000)
addition mutation <molecular biology> A type of mutation that results from insertion or deletion of a single nucleotide into, or from, an open reading frame in the normal DNA sequence.
Normally, the genetic code is read in the wrong frame, three nucleotides at a time, and the entire sequence downstream of the mutation, is translated into a polypeptide with a garbled amino acid sequence from the mutated codon onwards. These mutations may be induced by certain types of mutagens or may occur spontaneously and usually result in the generation, downstream, of nonsense, chain termination codons.
Synonym: addition mutation, addition-deletion mutation, deletion mutation, reading-frameshift mutation.
(21 Jun 2000)
amber mutation <molecular biology> A mutation from a codon which codes for an amino acid into the amber codon UAG, which normally signals that the translation of mRNA into an amino acid chain should stop.
The mutation causes the amino acid chain to stop forming before it is actually completed.
(09 Oct 1997)
back mutation <molecular biology> A mutation that causes a mutant gene to revert to its original wild-type base sequence.
Compare: forward mutation.
(09 Oct 1997)
reading-frameshift mutation <molecular biology> A type of mutation that results from insertion or deletion of a single nucleotide into, or from, an open reading frame in the normal DNA sequence.
Normally, the genetic code is read in the wrong frame, three nucleotides at a time, and the entire sequence downstream of the mutation, is translated into a polypeptide with a garbled amino acid sequence from the mutated codon onwards. These mutations may be induced by certain types of mutagens or may occur spontaneously and usually result in the generation, downstream, of nonsense, chain termination codons.
Synonym: addition mutation, addition-deletion mutation, deletion mutation, reading-frameshift mutation.
(21 Jun 2000)
germinal mutation A mutation in the germ cells (the cells which will undergo meiosis to form the gametes). Such mutations are therefore passed on to offspring.
(09 Oct 1997)
germ-line mutation Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.
(12 Dec 1998)
reverse mutation <molecular biology> A mutation that causes a mutant gene to revert to its original wild-type base sequence.
Compare: forward mutation.
(09 Oct 1997)
chromosomal mutation Can refer to any of a number of DNA mutations which results in a change in the protein encoded by the mutated gene, such as point mutations, insertion or deletion mutations (frameshift mutations), or nonsense mutations. More often this refers to mutations involving chromosomes, such as the inversion of part of one chromosome such that the inverted part no longer matches with its homologous pair, a translocation of one part of a chromosome to a different chromosome, deletions of parts of chromosomes, or accidents which happen during the division of the nucleus like the unequal portioning of chromosomes between the daughter cells.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • New Christian
    MARRANO
  • New Critic
    ½ÅºñÆò°¡
  • New Criticism
    ½ÅºñÆò
  • New Deal
    ´ºµôÁ¤Ã¥(Roosevelt ¹Ì±¹ ´ëÅë·ÉÀÌ 1933³â¿¡ Á¦Ã¢ÇÑ °æÁ¦ ºÎÈï°ú »çȸ º¸ÀåÀÇ ÁõÁø Á¤Ã¥)
  • New Delhi
    ´ºµ¨¸®(Àεµ °øÈ­±¹ÀÇ ¼öµµ
  • New Economic Policy
    ½Å°æÁ¦Á¤Ã¥,³×ÇÁ
  • New England
    ÀÌÁö¹æÀÌ ¿µ±¹ÇؾȰú ºñ½ÁÇÏ´ÙÇØ¼­ Captain John Smith°¢ ¸í¸í)´ºÀ×±Û·£µå¹Ì±¹ºÏµ¿ºÎÀÇ ¿©¼¸ÁÖConnecticut;Massachusetts;Rhode Island;Vermont;New Hampshire;Maine)
  • New Englander
    ´ºÀ×±Û·£µå »ç¶÷
  • New English Bible
    ½Å ¿µ¿ª¼º¼­(½Å¾à 1961³â,½Å±¸¾àÇÕº» 1970³â¿¡ °£Çà
  • New Federalism
    ½Å¿¬¹æÁÖÀÇ
  • New Frontier
    ´º ÇÁ·ÐƼ¾î(¹Ì±¹ ´ëÅë·É Á¸ ¿¡ÇÁ ÄɳʵðÀÇ Àû±ØÀûÀÎ Á¤Ã¥)Frontier
  • New Guinea
    ¿À½ºÆ®·¹Àϸ®¾Æ ºÏºÎÀÇ ¼¶
  • New Hampshire
    ¹Ì±¹ºÏµ¿ºÎÀÇ ÁÖ;´ºÇÜÇÁ¼Å
  • New Jersey
    (´©ÀúÁö)À̶¥À» ¹ÞÀº ¿µ±¹Á¦µ¶ÀÇ Ãâ½ÅÁö;Jersey¼¶ÀÇ À̸§À» µû¼­);¹Ì±¹ µ¿ºÎÀÇ ÁÖ
  • New Jerusalem
    »õ·Î¿î;¿¹·ç»ì·½;¼­¿Â;¿äÇÑ °è½Ã·Ï;Áö»ó³«¿ø;õ±¹
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á